Skip to content

The effect of a low compared to a high glycemic index/saturated fatty acid diet on hepatic fat

The effect of a low compared to a high glycemic index/saturated fatty acid diet on hepatic fat - GI/SFA diet and hepatic fat

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON54906
Enrollment
29
Registered
2019-07-03
Start date
2019-08-15
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatty liver Non-alcoholic fatty liver (NAFL)

Interventions

Participants will adhere to two diets differing in GI and SFA content for 2 weeks each: a two-week low GI/low SFA diet and a two-week high GI/high SFA diet. Diets will be comparable in macronutrient

Sponsors

Universiteit Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Signed informed consent - Caucasian (people will be excluded when having a *50% racial African/Asian background) - Male or postmenopausal female - Aged 45-75 years at start of the study - Body mass index (BMI) 27 * 38 kg/m2 - Stable dietary habits (no weight loss or gain >3kg in the past 3 months) - Sedentary lifestyle (not more than 2 hours of sports per week) - TG between 1.0 and 4.0 mmol/L

Exclusion criteria

Exclusion criteria: - Type 2 diabetes - Any acute condition, exacerbation of chronic condition, or medical history that would in the investigator*s or dependant physician's opinion interfere with the study - Contra-indication for MRI - Alcohol consumption of >2 servings per day - Smoking - Vegetarian, vegan, food intolerant to common foods (e.g. gluten intolerant, lactose intolerant) - Use of medication known to interfere with the safety of study procedures

Design outcomes

Primary

MeasureTime frame
Liver fat content (measured by 1H-MRS)

Secondary

MeasureTime frame
Explorative study parameters: - de novo lipogenesis (DNL) measured as relative contribution of newly synthesized palmitate in the VLDL-TG pool expressed as %DNL. - hepatic fat oxidation measured as plasma beta-hydroxybutyrate (BHB) - hepatic glycogen content (13C-MRS) - substrate oxidation - plasma metabolites related to energy metabolism - liver fat composition (1 H-MRS) - 24h glycemic response

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)